Abstract:Background: Drug-coated balloons (DCBs) have shown promising results in treating femoropopliteal artery lesions while data on infrapopliteal lesions are controversial. We undertook this clinical trial to compare the safety and efficacy of DCBs versus uncoated balloon percutaneous transluminal angioplasty (control) of de novo or recurrent steno-occlusive lesions of the infrapopliteal arteries in patients with critical limb ischemia. Methods: In this prospective multicenter single-blind randomized study, 120 patients were randomized to the DCB group (Litos/Tulip, Acotec Scientific; n=61) or control group treated with uncoated balloons (n=59) in 11 centers in China from May 22, 2014, to June 13, 2018. Follow-up was scheduled at one and six months and included angiographic assessment at six months. Adverse events were assessed by an independent clinical events committee, angiographic parameters by an independent core laboratory. The study is registered at ClinicalTrials.gov, number NCT02137577. Findings: Regarding the primary safety endpoint (composite of all-cause mortality, target extremity major amputation, and target lesion revascularization at 30 days), there was one event (1·6%) in the DCB group and none in the control group (p=0·33). The primary efficacy endpoint-primary patency (defined as absence of target vessel occlusion, major amputation, or target lesion revascularization) at six months was accomplished in 77·1% [95% Cl 65·2%-89%] of the DCB group and 28·3% [95% Cl 15·3%-41·3%] of control group (p<0·001). Freedom from clinically driven target lesion revascularization was 95·1% [95% Cl 89·5%-100%] versus 79·7% [95% Cl 69·7%-90·1%] (p < 0·01) and late lumen loss 0·35±0·74mm [95% Cl 0·14-0·56mm] versus 1·08±0·62mm [95% Cl 0·90-1·26mm] (p<0·001). Interpretation: The Litos/Tulip DCBs are safe and effective in treating infrapopliteal artery lesions, resulting in improved angiographic and clinical outcomes compared with uncoated balloon PTA. Trial Registration Number: The study is registered at ClinicalTrials.gov, number NCT02137577. Funding: Acotec. Declaration of Interest: We declare no competing interests. Ethical Approval: The trial was conducted in conformity with the Declaration of Helsinki and the provisions for the conduct of clinical trials of medical devices issued by the China Food and Drug Administration. It was approved by the Chinese PLA General Hospital Ethics Committee and other ten local ethics committees of participating hospitals in China. All patients gave written informed consent prior to any study procedure.

Drug‐coated Balloon for the Treatment of Small Vessel Disease: 9 Months of Angiographic Results and 12 Months of Clinical Outcomes of the PEPCAD China SVD Study

Comparison of Drug-Coated Balloon and Drug-Eluting Stent for the Treatment of Small Vessel Disease (from the Dissolve SVD Randomized Trial).

Biolimus-coated Versus Paclitaxel-Coated Balloons for Coronary In-Stent Restenosis (BIO ASCEND ISR): a Randomised, Non-Inferiority Trial.

Efficacy and Safety of Drug-Coated Balloons in the Treatment of De Novo Coronary Lesions in Very Small Vessels: a Prospective, Multicenter, Single-Arm Trial

A Non-inferiority, Randomized Clinical Trial Comparing Paclitaxel-Coated Balloon Versus New-Generation Drug-Eluting Stents on Angiographic Outcomes for Coronary De Novo Lesions

Drug-Coated Balloon Angioplasty Versus Standard Uncoated Balloon Angioplasty for Long Femoropopliteal Lesions: Post Hoc Analysis of the 24-Month Results of the AcoArt I Study

China Expert Consensus on Clinical Application of the Drug-Coated Balloon

A Randomized Comparison of Two Paclitaxel-Coated Balloons for the Treatment of In-Stent Restenosis: the LONGTY ISR China Randomized Trial (LONGTY DCB Vs. SeQuent Please DCB).

Treatment of Large De Novo Coronary Lesions with Paclitaxel-Coated Balloon Only: Results from a Chinese Institute

REAL-WORLD CLINICAL EVALUATION OF A PACLITAXEL-COATED BALLOON CATHETER IN SMALL VESSEL DE NOVO LESIONS

Optical Coherence Tomography-Guided Drug Coated Balloon in Non-Small De Novo Coronary Artery Lesions: a Prospective Clinical Research

Drug-Coated Balloon Versus Drug-Eluting Stent for Small-Vessel Disease

Long-term safety and efficacy of angioplasty of femoropopliteal artery disease with drug-coated balloons from the AcoArt I trial

A New Drug-Coated Balloon for the Treatment of Superficial Femoropopliteal Artery Disease: 12-Month Results from the IN-DEPT SFA Trial

Drug-coated balloon for vertebral artery origin stenosis: a pilot study

Drug-Coated Balloon Angioplasty Compared with Uncoated Balloons in the Treatment of Infrapopliteal Artery Lesions: 6-Month Results of a Randomized, Multi-Centers, Single-Blind, and Superiority Trial

Drug-coated balloons for the treatment of symptomatic intracranial atherosclerosis: initial experience and follow-up outcome

Effect of Drug-Coated Balloon in Side Branch Protection for de novo Coronary Bifurcation Lesions: A Systematic Review and Meta-Analysis

Drug-Coated balloons vs drug-eluting stents for the treatment of small coronary artery disease: A meta-analysis of randomized trials

Long-Term Clinical Outcomes After Percutaneous Coronary Intervention With Drug-Coated Balloon-Only Strategy in de novo Lesions of Large Coronary Arteries

Drug-Coated Balloon Angioplasty Compared with Uncoated Balloons in the Treatment of Infrapopliteal Artery Lesions (acoart II-BTK).